Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,342 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Atascadero, CaliforniaAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07389967Recruiting
Nutrition awareness study for women after breast cancer treatment
This study looks at how aware women are about nutrition after finishing their main breast cancer treatment. It aims to help improve support for diet and healthy eating habits.
Chapel Hill, North CarolinaAges 18 years+ - NCT07394062Recruiting
Comparing chemo-immunotherapy combinations for advanced lung cancer
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
AnkaraAges 18 years+ - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT04990921RecruitingPhase 2
Palliative radiation plus pembrolizumab for metastatic breast cancer
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Louisville, KentuckyAges 18 years+ - NCT07381764RecruitingPhase 2
Rechallenge with targeted drugs for certain colorectal cancers
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
AlessandriaAges 18 years+ - NCT06670911RecruitingPhase 2
Lower dose pembrolizumab with chemo for advanced cervical cancer
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT06841159RecruitingPhase 2
Personalized radiation plus immunotherapy and chemo for metastatic colorectal cancer
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
ShanghaiAges 18–75 - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT07361003RecruitingPhase 3
Testing suvemcitug plus chemo for refractory colorectal cancer
This trial tests a new drug, suvemcitug, combined with an oral chemotherapy called FTD/TPI for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+ - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT06611891RecruitingPhase 3
PET scan study for breast cancer with hormone receptors
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
GrenobleAges 18–99 - NCT07347600Recruiting
Studying inavolisib for a type of advanced breast cancer
This study tests a targeted therapy called inavolisib for people whose breast cancer has spread (advanced or metastatic), is hormone receptor-positive and HER2-negative, has a PIK3CA mutation, and has stopped responding to hormone therapy. It aims to see if inavolisib is safe and works well for them.
Xiamen, FujianAges 18 years+ - NCT07344220Enrolling by invitationPhase 2
Maintenance therapy study for stable metastatic pancreatic cancer
This trial tests a new drug, DZ-002, as maintenance therapy for people with metastatic pancreatic cancer whose disease has not worsened after at least 4 months of first-line chemotherapy. The goal is to help keep the cancer under control with fewer side effects.
Newport Beach, CaliforniaAges 18 years+ - NCT05825456Recruiting
Study of surgery for broken bones from metastatic cancer
This trial looks at outcomes after surgery to stabilize a broken bone caused by cancer that has spread (metastatic cancer). It may help by improving how doctors plan and measure results after specific types of bone stabilization surgery.
Ankara, altindagAges Any age - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07334587Enrolling by invitation
Comparing two chemotherapies for advanced colorectal cancer
This trial compares two chemotherapy drug combinations (FOLFOX-6 and CAPOX) to see which works better and has fewer side effects for people with colorectal cancer that has spread. It may help you and your doctor choose the best treatment option.
Lahore, Punjab ProvinceAges 20–70 - NCT07339878Recruiting
Choosing the first treatment for advanced bladder cancer
This study looks at the different ways doctors choose the first treatment for patients whose urothelial cancer has spread. It aims to understand what factors influence that choice, which could help improve care for future patients.
StrasbourgAges 18 years+ - NCT06778031RecruitingPhase 2
Study of SHR-A1811 for HER2-positive bile duct cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Harbin, HeilongjiangAges 18–75
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,342 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.